Chest CT scan plus x-ray versus chest x-ray for the follow-up of completely resected non-small-cell lung cancer (IFCT-0302) a multicentre, open-label, randomised, phase 3 trial

被引:43
作者
Westeel, Virginie [1 ,35 ]
Foucher, Pascal [2 ]
Scherpereel, Arnaud [3 ]
Domas, Jean [4 ]
Girard, Philippe [5 ]
Tredaniel, Jean [6 ]
Wislez, Marie [7 ]
Dumont, Patrick [8 ]
Quoix, Elisabeth [9 ]
Raffy, Olivier [10 ]
Braun, Denis [11 ]
Derollez, Marc [12 ]
Goupil, Francois [13 ]
Hermann, Jacques [14 ]
Devin, Etienne [15 ]
Barbieux, Hubert [16 ]
Pichon, Eric [17 ]
Debieuvre, Didier [18 ]
Ozenne, Gervais [19 ]
Muir, Jean-Francois [19 ]
Dehette, Stephanie [20 ]
Virally, Jerome [21 ]
Grivaux, Michel [22 ]
Lebargy, Francois [23 ]
Souquet, Pierre-Jean [24 ]
Al Freijat, Faraj [25 ]
Girard, Nicolas [26 ]
Courau, Emmanuel [27 ]
Azarian, Reza [28 ]
Farny, Michel [29 ]
Duhamel, Jean-Paul [30 ]
Langlais, Alexandra [31 ]
Morin, Franck [31 ]
Milleron, Bernard [7 ]
Zalcman, Gerard [32 ]
Barlesi, Fabrice [33 ,34 ]
机构
[1] Univ Bourgogne Franche Comte, Univ Hosp Besancon, Dept Pneumol, INSERM UMR1098, Besancon, France
[2] Univ Hosp Bocage, Dept Pneumol, Dijon, France
[3] Univ Lille, Inst Pasteur Lille, Thorac Oncol Dept, CHU Lille,UMR9020 UMR S 1277, UMR-S 1277-Canther, Lille, France
[4] Dept Oncol, Clin Perpignan, Perpignan, France
[5] Inst Curie Montsouris, Dept Pneumol, Paris, France
[6] St Joseph Hosp, Dept Pneumol, Paris, France
[7] Hop Tenon, Pneumol & Thorac Oncol, Paris, France
[8] Hosp Ctr Chauny, Pneumol Dept, Chauny, France
[9] Strasbourg Univ, Pneumol Nouvel Hop Civil, Hop Univ Strasbourg, Inserm UMR S 1113,IRFAC, Inserm UMR S 1113, Strasbourg, France
[10] Hosp Chartres, Dept Pneumol, Chartres, France
[11] Maillot Hosp, Dept Pneumol, Briey, France
[12] Maubeuge Hosp, Dept Pneumol, Maubeuge, France
[13] Univ Hosp Mans, Dept Pneumol, Le Mans, France
[14] Hosp Robert Schuman, Dept Pneumol, Metz, France
[15] Hosp Evreux, Dept Pneumol, Evreux, France
[16] Hosp Auxerre, Dept Oncol, Auxerre, France
[17] Univ Hosp Tours, Dept Pneumol, Tours, France
[18] GHRMSA, Dept Pneumol, Mulhouse, France
[19] Univ Hosp Rouen, Bois Guillaume, Dept Pneumol, Rouen, France
[20] Hosp Compiegne, Dept Pneumol, Compiegne, France
[21] Hosp Aulnay Sous Bois, Dept Pneumol, Aulnay Sous Bois, France
[22] Hosp Meaux, Dept Pneumol, Meaux, France
[23] Univ Hosp Reims, Dept Pneumol, Reims, France
[24] Hosp Lyon Sud, Dept Pneumol, Lyon, France
[25] Hosp Belfort, Dept Pneumol, Belfort, France
[26] Hop Cardiovasc & Pneumol Louis Pradel, Pneumol, Bron, France
[27] Clin Pasteur, Dept Pneumol, Toulouse, France
[28] Hosp Versailles, Dept Pneumol, Versailles, France
[29] Hosp Cahors, Pneumol Dept, Cahors, France
[30] Hosp Le Havre, Dept Pneumol, Le Havre, France
[31] Intergrp Francophone Cancerol Thorac, Paris, France
[32] Univ Paris Cite Bichat, Claude Bernard Hosp, AP HP, Inst Canc, Nord Paris, France
[33] Aix Marseille Univ, Multidisciplinary Oncol & Therapeut Innovat Dept, CNRS, INSERM,CRCM,APHM,CHU NORD, Campus Timone, Marseille, France
[34] Gustave Roussy Canc Campus, Villejuif, France
[35] Univ Hosp, Chest Dis & Thorac Oncol Dept, F-25030 Besancon, France
关键词
EARLY-STAGE; SURVEILLANCE; SURVIVAL; RECURRENCE; IMPACT; EPIDEMIOLOGY; PATTERNS; RISK;
D O I
10.1016/S1470-2045(22)00451-X
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Even after resection of early-stage non-small-cell lung cancer (NSCLC), patients have a high risk of developing recurrence and second primary lung cancer. We aimed to assess efficacy of a follow-up approach including clinic visits, chest x-rays, chest CT scans, and fibre-optic bronchoscopy versus clinical visits and chest x-rays after surgery for resectable NSCLC. Methods In this multicentre, open-label, randomised, phase 3 trial (IFCT-0302), patients aged 18 years or older and after complete resection of pathological stage I-IIIA NSCLC according to the sixth edition of the TNM classification were enrolled within 8 weeks of resection from 122 hospitals and tertiary centres in France. Patients were randomly assigned (1:1) to CT-based follow-up (clinic visits, chest x-rays, thoraco-abdominal CT scans, and fibre-optic bronchoscopy for non-adenocarcinoma histology) or minimal follow-up (visits and chest x-rays) after surgery for NSCLC, by means of a computer-generated sequence using the minimisation method. Procedures were repeated every 6 months for the first 2 years and yearly until 5 years. The primary endpoint was overall survival analysed in the intention-to-treat population. Secondary endpoints, also analysed in the intention-to-treat population, included disease-free survival. This trial is registered with ClinicalTrials.gov, NCT00198341, and is active, but not enrolling. Findings Between Jan 3, 2005, and Nov 30, 2012, 1775 patients were enrolled and randomly assigned to a follow-up group (888 patients to the minimal follow-up group; 887 patients to the CT-based follow-up group). Median overall survival was not significantly different between follow-up groups (8.5 years [95% CI 7.4-9.6] in the minimal follow-up group vs 10.3 years [8.1-not reached] in the CT-based follow-up group; adjusted hazard ratio [HR] 0.95, 95% CI 0.83-1.10; log-rank p=0.49). Disease-free survival was not significantly different between follow-up groups (median not reached [95% CI not estimable-not estimable] in the minimal follow-up group vs 4.9 [4.3-not reached] in the CT-based follow-up group; adjusted HR 1.14, 95% CI 0.99-1.30; log-rank p=0.063). Recurrence was detected in 246 (27.7%) of 888 patients in the minimal follow-up group and in 289 (32.6%) patients of 887 in the CT -based follow-up group. Second primary lung cancer was diagnosed in 27 (3.0%) patients in the minimal follow-up group and 40 patients (4.5%) in the CT-based follow-up group. No serious adverse events related to the trial procedures were reported. Interpretation The addition of thoracic CT scans during follow-up, which included clinic visits and chest x-rays after surgery, did not result in longer survival among patients with NSCLC. However, it did enable the detection of more cases of early recurrence and second primary lung cancer, which are more amenable to curative-intent treatment, supporting the use of CT-based follow-up, especially in countries where lung cancer screening is already implemented, alongside with other supportive measures. Copyright (C) Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:1180 / 1188
页数:9
相关论文
共 30 条
[1]   Early stage NSCLC - challenges to implementing ctDNA-based screening and MRD detection [J].
Abbosh, Christopher ;
Birkbak, Nicolai J. ;
Swanton, Charles .
NATURE REVIEWS CLINICAL ONCOLOGY, 2018, 15 (09) :577-586
[2]   Imaging surveillance and survival for surgically resected non-small-cell lung cancer [J].
Backhus, Leah M. ;
Farjah, Farhood ;
Liang, Chao-Kang Jason ;
He, Hao ;
Varghese, Thomas K., Jr. ;
Au, David H. ;
Flum, David R. ;
Zeliadt, Steven B. .
JOURNAL OF SURGICAL RESEARCH, 2016, 200 (01) :171-176
[3]   Does intensive follow-up alter outcome in patients with advanced lung cancer? [J].
Benamore, Rachel ;
Shepherd, Frances A. ;
Leighl, Natasha ;
Pintilie, Melania ;
Patel, Milan ;
Feld, Ronald ;
Herman, Stephen .
JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (04) :273-281
[4]   Threats to Validity of Nonrandomized Studies of Postdiagnosis Exposures on Cancer Recurrence and Survival [J].
Chubak, Jessica ;
Boudreau, Denise M. ;
Wirtz, Heidi S. ;
McKnight, Barbara ;
Weiss, Noel S. .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2013, 105 (19) :1456-1462
[5]   Follow-up and surveillance of the lung cancer patient following curative-intent therapy [J].
Colice, GL ;
Rubins, J ;
Unger, M .
CHEST, 2003, 123 (01) :272S-283S
[6]   Does the method of radiologic surveillance affect survival after resection of stage I non-small cell lung cancer? [J].
Crabtree, Traves D. ;
Puri, Varun ;
Chen, Simon B. ;
Gierada, David S. ;
Bell, Jennifer M. ;
Broderick, Stephen ;
Krupnick, A. Sasha ;
Kreisel, Daniel ;
Patterson, G. Alexander ;
Meyers, Bryan F. .
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2015, 149 (01) :45-+
[7]   This Week in the Journal [J].
de Koning, H. J. ;
van der Aalst, C. M. ;
de Jong, P. A. ;
Scholten, E. T. ;
Nackaerts, K. ;
Heuvelmans, M. A. ;
Lammers, J. -W. J. ;
Weenink, C. ;
Yousaf-Khan, U. ;
Horeweg, N. ;
van't Westeinde, S. ;
Prokop, M. ;
Mali, W. P. ;
Hoesein, F. A. A. Mohamed ;
van Ooijen, P. M. A. ;
Aerts, J. G. J. V. ;
den Bakker, M. A. ;
Thunnissen, E. ;
Verschakelen, J. ;
Vliegenthart, R. ;
Walter, J. E. ;
ten Haaf, K. ;
Groen, H. J. M. ;
Oudkerk, M. .
NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (06) :503-513
[8]   Two-Year Survival Comparing Web-Based Symptom Monitoring vs Routine Surveillance Following Treatment for Lung Cancer [J].
Denis, Fabrice ;
Basch, Ethan ;
Septans, Anne-Lise ;
Bennouna, Jaafar ;
Urban, Thierry ;
Dueck, Amylou C. ;
Letellier, Christophe .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2019, 321 (03) :306-307
[9]   Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial [J].
Felip, Enriqueta ;
Altorki, Nasser ;
Zhou, Caicun ;
Csoszi, Tibor ;
Vynnychenko, Ihor ;
Goloborodko, Oleksandr ;
Luft, Alexander ;
Akopov, Andrey ;
Martinez-Marti, Alex ;
Kenmotsu, Hirotsugu ;
Chen, Yuh-Min ;
Chella, Antonio ;
Sugawara, Shunichi ;
Voong, David ;
Wu, Fan ;
Yi, Jing ;
Deng, Yu ;
McCleland, Mark ;
Bennett, Elizabeth ;
Gitlitz, Barbara ;
Wakelee, Heather .
LANCET, 2021, 398 (10308) :1344-1357
[10]   Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer [J].
Forde, Patrick M. ;
Spicer, Jonathan ;
Lu, Shun ;
Provencio, Mariano ;
Mitsudomi, Tetsuya ;
Awad, Mark M. ;
Felip, Enriqueta ;
Broderick, Stephen R. ;
Brahmer, Julie R. ;
Swanson, Scott J. ;
Kerr, Keith ;
Wang, Changli ;
Ciuleanu, Tudor-Eliade ;
Saylors, Gene B. ;
Tanaka, Fumihiro ;
Ito, Hiroyuki ;
Chen, Ke-Neng ;
Liberman, Moishe ;
Vokes, Everett E. ;
Taube, Janis M. ;
Dorange, Cecile ;
Cai, Junliang ;
Fiore, Joseph ;
Jarkowski, Anthony ;
Balli, David ;
Sausen, Mark ;
Pandya, Dimple ;
Calvet, Christophe Y. ;
Girard, Nicolas .
NEW ENGLAND JOURNAL OF MEDICINE, 2022, 386 (21) :1973-1985